Krishna Ibrahimpatnam
About Krishna Ibrahimpatnam
Krishna Ibrahimpatnam has 12 years in corporate governance. Holds Director role. Currently with 2 companies, including A9a Pharmaceuticals Private Limited and Metax Life Sciences Limited. Formerly with 2 companies, such as Proven Chemicals Limited and Teckbond Laboratories Private Limited. Engaged in General Business. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
A9a Pharmaceuticals Private Limited
U24100TG2020PTC141421
|
Director | 05 Jul 2020 | 2020 | Active |
|
Metax Life Sciences Limited
U24230TG2000PLC035486
|
Director | 20 Mar 2025 | 2000 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
|
Proven Chemicals Limited
U24110TG1988PLC008377
|
Director | 16 Apr 2019 | 1988 | Active |
Teckbond Laboratories Private Limited
U24239TG2004PTC042470
|
Director | 02 Feb 2014 | 2004 | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Krishna Ibrahimpatnam
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Krishna Ibrahimpatnam
Krishna Ibrahimpatnam has 12 years in corporate governance. Holds Director role. Currently with 2 companies, including A9a Pharmaceuticals Private Limited and Metax Life Sciences Limited. Formerly with 2 companies, such as Proven Chemicals Limited and Teckbond Laboratories Private Limited. Engaged in General Business. Contributes to corporate operations.
Krishna Ibrahimpatnam is associated with 2 companies as Director.
Krishna Ibrahimpatnam has expertise in General Business.
Krishna Ibrahimpatnam has 12 years in corporate governance.